Which is better, LBRX or MTD?

On the Buffett-Fit framework, Mettler-Toledo International Inc. (MTD) currently grades higher than LBRX — 69/100 (B grade) vs 42/100 (D). That said, "better" depends on which framework you trust — LBRX wins on none; MTD wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy LBRX or MTD?

This page is an educational comparison, not investment advice. Both LBRX and MTD are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is LBRX better than MTD for value investing?

On the Buffett-style value-investing framework, MTD currently grades higher — 69/100 vs 42/100, a 27-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between LBRX and MTD on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). LBRX currently scores 42/100 (D grade); MTD scores 69/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, LBRX or MTD?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. LBRX and MTD are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, LBRX or MTD?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are LBRX and MTD both Healthcare stocks?

Yes — both LB Pharmaceuticals Inc Common Stock (LBRX) and Mettler-Toledo International Inc. (MTD) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this LBRX vs MTD comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

LB Pharmaceuticals

Mettler-Toledo International

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

LBRX

LB Pharmaceuticals

Market cap

$806.39M

Sector

Healthcare

MTD

Mettler-Toledo International

Market cap

$22.29B

Sector

Healthcare

Overall winner

Mettler-Toledo International MTD

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	LBRX	MTD	Winner
Warren Buffett	42D	69B	MTD
Benjamin Graham	50D	65B	MTD
Philip Fisher	53C	63C	MTD
Peter Lynch	12F	66B	MTD
Joel Greenblatt	2F	68B	MTD
Charlie Munger	55D	74B	MTD
Terry Smith	64C	70B	MTD

Side-by-side metrics

Metric	LBRX	MTD
Market cap	$806.39M	$22.29B
P/E (TTM)	-	25.3x
EV/EBIT	-	21.6x
ROIC (TTM)	-9.93%	36.09%
Gross margin	0.0%	57.79%
Net margin	0.0%	21.4%
Revenue CAGR 5y	-	2.01%
EPS CAGR 5y	-	6.12%
Debt / Equity	0.0x	-
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LBRX leads on

EV/EBIT-vs 21.6x+198%
P/E (TTM)-vs 25.3x+181%

MTD leads on

ROIC (TTM)36.09%vs -9.93%+128%
Debt / Equity-vs 0.0x+100%
Gross margin57.79%vs 0.0%+100%
Net margin21.4%vs 0.0%+100%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

LB Pharmaceuticals

Mettler-Toledo International

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like LBRX

More like MTD

Related on invest-like

Key terms in this analysis